Hikma's Leucovorin Calcium ANDA072735 Receives Abbreviated Approval
Hikma's application ANDA072735 for Leucovorin Calcium has received abbreviated approval from the FDA.
Published: July 12, 2026
Updated: July 12, 2026
Author: Humanexa Intelligence
Therapeutic area: Oncology / Chemotherapy Adjunct
Company: Hikma
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Hikma
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
Hikma's abbreviated approval for Leucovorin Calcium signifies a new entrant in the oncology market, which could disrupt existing pricing structures and market shares. Pharma strategy teams should closely monitor Hikma's market entry and competitive responses to maintain their positioning.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market launch timelines and pricing strategies from Hikma and competitors.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.